Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 8, 2004, Pages 1236-1240

  Nakao, Hiromi ^a   Senokuchi, Kaori ^a   Umebayashi, Chisato ^a   Kanemaru, Kaori ^a   Masuda, Toshiya ^a,b   Oyama, Yasuo ^a   Yonemori, Shigetomo ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Cytotoxicity; Human leukemia K562 cell; Maytanprine; Maytenus diversifolia

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MAYTANPRINE; MAYTANSINE; METHANOL; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL GROWTH; CELL POPULATION; CELL STRAIN K 562; CELL SUBPOPULATION; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIPLOIDY; DRUG CYTOTOXICITY; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA; MAYTENUS DIVERSIFOLIA; MEDICINAL PLANT; DRUG EFFECT; ISOLATION AND PURIFICATION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; FLOW CYTOMETRY; HUMANS; K562 CELLS; MAYTANSINE;

EID: 16644389223     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.1236     Document Type: Article

References (17)

1. Noble R. L., Biochem. Cell Biol., 68, 1344-1351 (1990).
2. Huxtable R. J., J. Ethnopharmacol., 37, 1-11 (1992).
3. Kingston D. G. I., "Human Medicinal Agents from Plants," American Chemical Society, Washington, D.C., 1993, pp. 138-148.
4. Chikahisa L., Oyama Y., Iguchi Y., Okazaki E., Miyoshi N., Satoh M., Yamada Y., Environ. Toxicol. Pharmacol., 6, 209-215 (1998).
5. Masuda T., Oyama Y., Yonemori S., Takeda Y., Yamazaki Y., Mizuguchi S., Nakata M., Tanaka T., Chikahisa L., Inaba Y., Okada Y., Phytother. Res., 16, 353-358 (2001).
6. Kupchan S. M., Komoda Y., Court W. A., Thomas G. J., Smith R. M., Karim A., Gilmore C. J., Haltiwanger R. C., Bryan R. F., J. Am. Chem. Soc., 94, 1354-1356 (1972).
7. Cassady J. M., Chan K. K., Floss H. G., Lestner E., Chem. Pharm. Bull., 52, 1-26 (2004).
8. Remillard S., Rebhun L. I., Howie G. A., Kupchan S. M., Science, 189, 1002-1005 (1975).
9. Umebayashi C., Oyama Y., Chikahisa-Muramatsu L., Nakao H., Nishizaki Y., Nakata M., Soeda F., Takahama K., Toxicol. In Vitro, 18, 55-61 (2004).
10. Masuda T., Oyama Y., Yamamoto N., Umebayashi C., Nakao H., Toi Y., Takeda Y., Nakamoto K., Kuninaga H., Nishizato Y., Nakata A., Biosci. Biotechnol. Biochem., 67, 1401-1404 (2001).
11. Nakao H., Umebayashi C., Nakata M., Nishizaki Y., Noda K., Okano Y., J. Pharmacol. Sci., 91, 83-86 (2003).
12. Umebayashi C., Yamamoto N., Nakao H., Toi Y., Chikahisa-Muramatsu L., Kanemaru K., Masuda T., Oyama Y., Biol. Pharm. Bull., 26, 627-630 (2003).
13. Wolf C. M., Reynolds J. E., Morana S. J., Eastman A., Exp. Cell Res., 230, 22-27 (1997).
14. Hughes F. M., Cidlowski J. A., J. Steroid. Biochem. Molec. Biol., 65, 207-217 (1998).
15. Maeno E., Ishizaki Y., Kanaseki T., Hazama A., Okada Y., Proc. Natl. Acad. Sci. U.S.A., 97, 9487-9492 (2000).
16. Beavais F., Michel L., Dubertret L., J. Leukoc. Biol., 57, 851-855 (1995).
17. Ravry M. J. R., Omura G. A., Birch R., Am. J. Clin. Oncol., 8, 148-150 (1985).